1910 Genetics

Today we announced a groundbreaking five-year commercial agreement and go-to-market collaboration with Microsoft to build the infrastructure layer for drug discovery using #AI and high performance computing.   This first of its kind, fully integrated, drug discovery and development platform will combine 1910’s massive, computational and wet lab biological data, robotics-driven laboratory automation and multimodal AI models for drug discovery with Microsoft’s next-generation high-performance computing platform, Azure Quantum Elements.   The platform will be offered to potential pharmaceutical, biotechnology, government, academic, and research institutions via three partnership models: Co-discovery, Co-engineering, and Platform-as-a-Service.   Together we will accelerate scientific discovery and empower pharmaceutical R&D teams worldwide to generate therapeutics faster and more cost-effectively. Press Release: https://lnkd.in/eHwmiNXH Customer Sign-up Form: https://lnkd.in/ek9dbk3T 

Congratulations to Liping Wu, PhD, Lakshmi Gayitri Chivukula, Francis Acquah, and Sidharth S. on their promotions. The 1910 Genetics team appreciates you for bringing our “Grit, Mission Driven, and Sense of Ownership” values to life!    To learn more about our values and open roles, please visit our careers page: https://lnkd.in/eMAeMkBs     #AIInnovation #Biology #1910Genetics

Last Saturday, our Founder & CEO, Jen Nwankwo, Ph.D. was the Opening Keynote Speaker at the Biomedical Science Careers Program (BSCP) Alumni Conference at Harvard Medical School.   In her Keynote speech, "A Conversation on Courageous & Inclusive Leadership," she reflected on the courage it took to found 1910 Genetics, and how courage requires privilege, which is all too often lacking for people of color.   Our CEO's Keynote Speech set the tone for the rest of the day, including the panel she moderated featuring incredible leaders - Dennise A. De Jesús-Díaz, Emerson Foster, and Mark M Melendez MD, MBA. Jen's authenticity about the challenges and triumphs of leadership resonated deeply with the audience. The day was filled with inspiring conversations, including a fireside chat with Dr. Joan Reede and Dr. Uché Blackstock, MD, highlighting their remarkable journeys and contributions to medicine.     We're excited about the future and the potential collaborations inspired by this conference. Thank you to everyone who made this event memorable.     #BSCP2024 #InclusiveLeadership #1910Genetics

Thank you Drug Discovery & Development for covering our Microsoft Azure Quantum collaboration which will provide pharma companies an integrated drug discovery and development platform combining AI, advanced computing, and laboratory automation to accelerate pharmaceutical R&D.    With fewer iterations needed to reach the final molecule for clinical trials, we're on track to significantly shorten the drug discovery process and deliver higher-quality drug candidates to the market faster than ever before.   We're excited to offer our platform via Co-Discovery, Co-Engineering, and Platform-as-a-Service partnership models to customers. Learn more here: https://lnkd.in/ek9dbk3T    Read the article here: https://lnkd.in/dAPz_rXZ    Thank you Brian K. Buntz!    #Biotech #AI #DrugDiscovery #Microsoft #AzureQuantum #1910Genetics 

Boston Business Journal covered our partnership with Microsoft which supports our mission to accelerate pharmaceutical R&D more affordably for pharma, biotechnology, government, academic, and research institutions worldwide. Our CEO and founder, Jen Nwankwo, Ph.D., shared, “Microsoft is one of the best companies in the world at building enterprise and global-scale software. [1910 Genetics is] really good at doing drug discovery and when the both of us come together, it’s almost like drug discovery on steroids.”    We're excited to offer our platform via Co-Discovery, Co-Engineering, and Platform-as-a-Service partnership models to customers. Learn more here: https://lnkd.in/ek9dbk3T Read the Boston Business Journal article here: https://lnkd.in/eRdri9YH    Thank you Hannah Green for this feature!    #1910Genetics #Microsoft #DrugDiscovery #AI 

Our founder and CEO Jen Nwankwo, Ph.D. sat with Genetic Engineering & Biotechnology News to discuss our differentiated multimodal data strategy, which integrates computational data, wet lab proxy biological data, and wet lab ground truth biological data to overcome the low data regime problem that has historically limited the application of state-of-the-art foundational models in the pharmaceutical industry.    To advance small and large molecule drug discovery, we employ a multimodal AI platform powered by laboratory automation. Our platform’s name—Input, Transform, Output (ITO)—reflects our company’s comprehensive approach, spanning proprietary data generation, data orchestration, AI, and high throughput laboratory automation in iterative training and testing loops.    To gain access to our ITO platform, click here: https://lnkd.in/ek9dbk3T  Read the full GEN feature: https://lnkd.in/gynQxCjF   

We were featured in the American Chemical Society's C&EN for our approach to democratizing access to our drug discovery and development platform.   Our recent partnership with Microsoft Azure Quantum Elements has supercharged our computing capabilities, enabling us to expand our services.    In line with this partnership, we provide drug discovery services via traditional models so that drug companies can codiscover, engineer, or license drugs; additionally, our Platform as a Service (PasS) model allows researchers to harness the power of our AI platform directly.    Find out more about our partnering models here: https://lnkd.in/ek9dbk3T   Read the full Chemical & Engineering News feature: https://lnkd.in/dRhvQ6Qg 

We're proud to be featured in Inc. Magazine for our collaboration with Microsoft to revolutionize drug discovery! Led by Jen Nwankwo, Ph.D., 1910 Genetics is leveraging AI to accelerate R&D and bring therapies to patients faster.   In collaboration with Microsoft, we're embarking on a five-year journey to accelerate R&D productivity, reshaping the landscape of drug discovery and development. With the average timeline and cost of bringing new drugs to market staggering, our partnership signifies a bold step towards a future where breakthrough therapeutics reach patients faster and more affordably.    As we continue to raise the bar and push boundaries, we invite you to join us on this incredible journey.    Interested partners can sign up here:  https://lnkd.in/ek9dbk3T    Together, we can redefine what's possible in biotech, one breakthrough at a time.    Thank you to Farrell Evans for this write-up!    Learn more about Jen’s journey: https://lnkd.in/eMHfBa5j    #1910Genetics #Microsoft #AI #BiotechInnovation 

Our Founder-CEO Jen Nwankwo, Ph.D. spoke with Brian K. Buntz for the AI Meets Life Sci podcast recently about what sets 1910 Genetics apart from other #AI #biotech companies, why she started the company, and what makes our team uniquely poised to solve real problems in drug discovery. Said Jen: "I didn’t start the company with a shiny ML tool in search of a problem. From the get go we’ve been clear eyed about being a biotechnology company. What that means is measuring ourselves by drugs and drug candidates. That North Star has been a big influence on strategy and it’s influenced the way we build the team; equal parts computational folks, biology folks, seasoned drug discovery executives who have put drugs in the clinic and brought drugs to market, as well as very energetic machine learning scientists.” To learn more about our strategy, and get a teaser of what's to come for 1910 Genetics in 2024, view the full interview via the link below: https://lnkd.in/gXyC56UY

We are excited to announce that Shaan Gandhi, MD, DPhil joined 1910 Genetics as an independent board director! Dr. Gandhi is VP and Head of Strategic Partnerships for Pfizer Ignite where he works closely with biotech companies to create opportunities for collaboration that accelerate therapeutic innovation. As part of our board, he will provide a critical clinical perspective alongside an extensive background in biotech investing and strategic partnering. This at the same time as 1910 Genetics continues to expand our pharma and tech partnerships, and advance our pipeline of #AI derived therapeutics. Said Dr. Gandhi: “1910 Genetics has clear line of sight to significant value creation in 2024 and beyond, due to its unique approach to drug discovery enabled by AI, data and optimized compute, its ability to partner with industry leaders, and a dedicated, experienced, and innovative team, led by Jen Nwankwo. I can’t wait to see what the future holds for this team and to help support their work to make a mark in healthcare and the life sciences.” Please join us in welcoming Dr. Gandhi to the team! #BoardofDirectors #TechBio #Biotech https://lnkd.in/gWsAJ_vM